Form 4: Schrodinger Executive Karen Akinsanya Reports Stock and Option Grants

Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On March 3, 2025, Karen Akinsanya, President of R&D, Therapeutics at Schrodinger, Inc., was granted 15,625 restricted stock units (RSUs) and options to purchase 62,500 shares of common stock.
• The RSUs vest in equal installments annually from March 4, 2026, to March 4, 2029, contingent upon continued service with the company.
• The stock options, with an exercise price of $21.24, vest 25% on March 3, 2026, and the remainder in equal monthly installments through March 3, 2029.
• Following these transactions, Akinsanya beneficially owns 15,625 shares of common stock in the form of unvested RSUs and options to purchase 62,500 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The grant of RSUs and stock options aligns Akinsanya's interests with those of the shareholders, incentivizing her to drive long-term value for the company.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment to Schrodinger.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Granting equity to key executives is a common practice in the biotech and pharmaceutical industries to align management's interests with those of shareholders and incentivize long-term growth.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded companies, particularly in the technology and biotechnology sectors.
• Companies like Relay Therapeutics, Recursion Pharmaceuticals, and Exscientia also utilize similar equity-based compensation plans to attract and retain talent.
• The vesting schedules described are typical, with vesting occurring over a multi-year period to ensure continued service and commitment.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates